More on SPTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.8 Score)

Upcoming Events

- Earnings (12/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:SPTX)
Delayed: 17.15 -1 (5.51%)
Prev. Close $18.15  
Open$18.14 
52 Wk High$ 
52 Wk Low$ 
Day High$18.14 
Day Low$17.04 
P/E N/A  
EPS$ 
Volume126,006 

Friends, Peers and Foes (?): PRTC (more...)

Oct 9, 2026 01:00 PM Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP
Oct 9, 2026 01:00 PM PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Oct 9, 2026 07:00 AM Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP
Oct 9, 2026 07:00 AM Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Oct 8, 2026 07:04 AM H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)
Oct 7, 2026 01:00 PM Seaport Therapeutics doses first patient in anxiety disorder trial
Oct 7, 2026 01:00 PM PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Oct 7, 2026 07:00 AM Seaport Therapeutics doses first patient in GlyphAgo anxiety trial
Oct 7, 2026 07:00 AM Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Sep 25, 2026 06:06 AM Raymond James Starts Seaport Therapeutics (SPTX) at Strong Buy
View All Articles

Entities mentioned with SPTX

View All Entities